{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Humana, Inc. technically bullish or bearish?
As of October 31, 2025, Humana, Inc. shows a mildly bullish technical trend, supported by bullish weekly MACD and daily moving averages, but tempered by mixed signals from the weekly KST and monthly Bollinger Bands, while underperforming the S&P 500 year-to-date and over the past year.
Humana, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Humana, Inc. has recently revised its evaluation amid fluctuating market conditions, with its stock showing a slight increase. Over the past year, the company has experienced significant trading activity. Despite some mixed technical indicators, Humana's returns have lagged behind the S&P 500 across various time frames, reflecting ongoing challenges.
Is Humana, Inc. technically bullish or bearish?
As of October 31, 2025, Humana, Inc. has a mildly bullish technical trend, with mixed signals from Bollinger Bands and a year-to-date return of 10.33%, underperforming the S&P 500's 16.30%.
Is Humana, Inc. technically bullish or bearish?
As of October 31, 2025, Humana, Inc. shows a mildly bullish technical trend, with mixed performance indicators and significant underperformance over the long term compared to the S&P 500.
Is Humana, Inc. technically bullish or bearish?
As of October 31, 2025, Humana, Inc. shows a mildly bullish technical trend, with mixed signals from Bollinger Bands and underperformance compared to the S&P 500 over the past 1, 3, and 5 years.
Humana, Inc. Hits Day High with Strong 10.56% Intraday Surge
Humana, Inc. has seen a notable increase in its stock performance, reaching an intraday high of USD 287.32. While it has outperformed the S&P 500 recently, the company has faced longer-term challenges. Humana reported a net profit of USD 1,789 million in March 2025 and maintains a strong return on equity.
Is Humana, Inc. technically bullish or bearish?
As of September 10, 2025, Humana, Inc. shows a bullish trend with positive momentum indicators, but it has underperformed the S&P 500, warranting caution due to mixed signals in longer timeframes.
Is Humana, Inc. overvalued or undervalued?
As of June 30, 2025, Humana, Inc. is considered overvalued with a P/E ratio of 26 compared to Centene Corp.'s 6.94, an EV to EBITDA of 37.39 versus Centene's 11.91, and has underperformed the S&P 500 with a 1-year return of -15.99% and a 3-year return of -47.01%.
Is Humana, Inc. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data for Humana, Inc. to determine if it is bullish or bearish.
Is Humana, Inc. overvalued or undervalued?
As of October 5, 2023, Humana, Inc. is considered attractive and undervalued with a P/E ratio of 18.5 and a P/B ratio of 3.2, outperforming peers like UnitedHealth Group and Anthem, Inc., and has outperformed the Sensex over the past year.
Who are in the management team of Humana, Inc.?
As of March 2022, Humana, Inc.'s management team includes Independent Chairman Kurt Hilzinger, CEO Bruce Broussard, and several Independent Directors: Frank Bisignano, Raquel Bono, Frank D'Amelio, Wayne Frederick, and John Garratt.
What does Humana, Inc. do?
Humana, Inc. is a large-cap health and well-being company in the Healthcare Services industry, with a market cap of approximately $46.07 billion and a quarterly net profit of $1.24 billion. Key metrics include a P/E ratio of 26.00, a dividend yield of 3.78%, and a return on equity of 9.67%.
How big is Humana, Inc.?
As of Jun 18, Humana, Inc. has a market capitalization of $46.07 billion, with recent net sales of $0 million and a net profit of $1.72 billion. The company reported shareholder's funds of $16.38 billion and total assets of $46.31 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
